Sotera Health (NASDAQ:SHC) Earns Neutral Rating from Analysts at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of Sotera Health (NASDAQ:SHC) in a report released on Friday, MarketBeat Ratings reports. The brokerage issued a neutral rating and a $14.00 price objective on the stock.

A number of other research analysts have also recently issued reports on the company. Citigroup lifted their price objective on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research report on Thursday, November 21st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.08.

Sotera Health Trading Up 1.2 %

Shares of Sotera Health stock opened at $13.13 on Friday. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44. The company’s fifty day simple moving average is $14.89 and its 200-day simple moving average is $14.11. The company has a market cap of $3.72 billion, a price-to-earnings ratio of 52.52 and a beta of 1.96. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The company’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.18 earnings per share. As a group, sell-side analysts expect that Sotera Health will post 0.61 EPS for the current year.

Hedge Funds Weigh In On Sotera Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wedmont Private Capital grew its stake in Sotera Health by 6.5% in the third quarter. Wedmont Private Capital now owns 10,915 shares of the company’s stock valued at $169,000 after purchasing an additional 664 shares in the last quarter. First Citizens Bank & Trust Co. raised its position in Sotera Health by 5.0% during the third quarter. First Citizens Bank & Trust Co. now owns 14,287 shares of the company’s stock worth $239,000 after acquiring an additional 677 shares in the last quarter. CWM LLC lifted its stake in Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after acquiring an additional 993 shares during the last quarter. GAMMA Investing LLC grew its holdings in Sotera Health by 125.0% during the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after purchasing an additional 1,660 shares during the period. Finally, TD Asset Management Inc boosted its stake in shares of Sotera Health by 1.5% during the 2nd quarter. TD Asset Management Inc now owns 123,454 shares of the company’s stock worth $1,465,000 after acquiring an additional 1,800 shares during the period. 91.03% of the stock is owned by institutional investors and hedge funds.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.